Australien - engelska - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - water for injections, quantity: 5.4 ml - injection, solution - excipient ingredients: - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for:,? control and prevention of bleeding episodes,? routine prophylaxis to prevent or reduce the frequency of bleeding episodes,? perioperative management (surgical prophylaxis),adynovate is not indicated for the treatment of von willebrand disease.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - water for injections, quantity: 5.4 ml - injection, solution - excipient ingredients: - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for:,? control and prevention of bleeding episodes,? routine prophylaxis to prevent or reduce the frequency of bleeding episodes,? perioperative management (surgical prophylaxis),adynovate is not indicated for the treatment of von willebrand disease.

Malta - engelska - Medicines Authority

baxalta innovations gmbh industriestrasse 67, 1221, vienna, austria - octocog alfa - powder and solvent for solution for injection - octocog alfa 25 iu/ml - antihemorrhagics

Malta - engelska - Medicines Authority

baxalta innovations gmbh industriestrasse 67, 1221, vienna, austria - octocog alfa - powder and solvent for solution for injection - octocog alfa 500 iu - antihemorrhagics

Malta - engelska - Medicines Authority

baxalta innovations gmbh industriestrasse 67, 1221, vienna, austria - octocog alfa - powder and solvent for solution for injection - octocog alfa 1000 iu - antihemorrhagics

Europeiska unionen - engelska - EMA (European Medicines Agency)

bayer ag  - octocog alfa - hemophilia a - antihemorrhagics - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor-viii deficiency).this preparation does not contain von willebrand factor and is therefore not indicated in von willebrand's disease.

Europeiska unionen - engelska - EMA (European Medicines Agency)

bayer ag - damoctocog alfa pegol - hemophilia a - antihemorrhagics - treatment and prophylaxis of bleeding in previously treated patients ≥ 12 years of age with haemophilia a (congenital factor viii deficiency).

Europeiska unionen - engelska - EMA (European Medicines Agency)

bayer ag - octocog alfa - hemophilia a - antihemorrhagics - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).iblias can be used for all age groups.

Europeiska unionen - engelska - EMA (European Medicines Agency)

baxalta innovations gmbh - susoctocog alfa - hemophilia a - antihemorrhagics - treatment of bleeding episodes in patients with acquired haemophilia caused by antibodies to factor viii. obizur is indicated in adults.

Europeiska unionen - engelska - EMA (European Medicines Agency)

baxalta innovations gmbh - rurioctocog alfa pegol - hemophilia a - antihemorrhagics - treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia a (congenital factor viii deficiency).